| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.8.15.2505 |
| P698 | PubMed publication ID | 17931086 |
| P50 | author | Evelina Tacconelli | Q87722568 |
| Maria Adriana Cataldo | Q87723103 | ||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study | Q24684202 | ||
| Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States | Q25257335 | ||
| Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms | Q28374448 | ||
| Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. | Q30330106 | ||
| Screening for methicillin-resistant Staphylococcus aureus in the endemic hospital: what have we learned? | Q31851429 | ||
| Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program | Q33346036 | ||
| Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study | Q33362269 | ||
| Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects | Q33554391 | ||
| Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis | Q33594048 | ||
| Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator | Q33980853 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene | Q34188059 | ||
| Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study | Q34268116 | ||
| Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center | Q34270638 | ||
| The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges | Q34401421 | ||
| Use of antibiotic locks to treat colonized central venous catheters | Q34419369 | ||
| Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y | Q34426508 | ||
| Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control | Q34468867 | ||
| Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study | Q34509652 | ||
| Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia | Q34509676 | ||
| Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| The evolution and role of macrolides in infectious diseases | Q34768513 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals | Q34973784 | ||
| Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 | ||
| Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy | Q36183890 | ||
| The pharmacokinetic and pharmacodynamic profile of tigecycline | Q36218318 | ||
| Antibiotic resistance in Staphylococcus aureus and its relevance in therapy | Q36283731 | ||
| Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections | Q36300916 | ||
| Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). | Q36306687 | ||
| Diagnosis and management of Staphylococcus aureus bacteraemia. | Q36306692 | ||
| Glycopeptides: Update on an old successful antibiotic class | Q36368315 | ||
| Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. | Q36409465 | ||
| Dalbavancin: a new option for the treatment of gram-positive infections | Q36409507 | ||
| Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin | Q36490311 | ||
| Update on daptomycin: the first approved lipopeptide antibiotic | Q36521880 | ||
| Clinical experience with recently approved antibiotics | Q36563856 | ||
| Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital | Q39035893 | ||
| The comparative efficacy and safety of teicoplanin and vancomycin | Q39601973 | ||
| BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 | ||
| In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations | Q40164266 | ||
| Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus | Q40216245 | ||
| Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome | Q40491682 | ||
| Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus | Q41269406 | ||
| Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis | Q41847174 | ||
| Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin | Q41847350 | ||
| Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases | Q43944136 | ||
| Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates | Q43998594 | ||
| Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies | Q44021450 | ||
| Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens | Q44066110 | ||
| Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization | Q44340945 | ||
| Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia | Q44453815 | ||
| Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin | Q44479148 | ||
| Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia | Q44647040 | ||
| Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology | Q44696141 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains | Q44755226 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia | Q44978559 | ||
| Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule | Q45097031 | ||
| Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? | Q45228183 | ||
| Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens | Q45237058 | ||
| In vivo synergy of daptomycin plus a penicillin agent for MRSA? | Q45244908 | ||
| Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program | Q46476476 | ||
| Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents | Q46654685 | ||
| In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). | Q46654694 | ||
| Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies | Q46728767 | ||
| Risk factors for ICU-acquired methicillin-resistant Staphylococcus aureus infections | Q46916434 | ||
| Staphylococcus aureus bacteremia in older adults: predictors of 7-day mortality and infection with a methicillin-resistant strain. | Q51910588 | ||
| Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. | Q53902357 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| P304 | page(s) | 2505-2518 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Antimicrobial therapy of Staphylococcus aureus bloodstream infection | |
| P478 | volume | 8 |
Search more.